Oramed Pharmaceuticals Inc (ORMP) — Titan Protect Analysis

ORMP

Oramed Pharmaceuticals Inc

Healthcare · ·

$3.71

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$151M

Total market value of the company

Trailing P/E

1.42

Very cheap relative to earnings

Forward P/E

-46.13

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

58.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$6.25

+68% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 1 analysts covering this stock

About Oramed Pharmaceuticals Inc

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New Y

https://oramed.com

Country: United States Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.857

Good returns relative to risk taken

Kelly Fraction

0.0104

Marginal edge — very small allocation suggested

Calmar Ratio

1.428

Returns exceed worst-case losses — strong risk profile

Annual Return

36.2%

Historical annualised return based on price data

Max Drawdown

-25.4%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.26

Moves slightly more than the broader market

52W High

$5.01

26% below the year high

52W Low

$1.98

87% above the year low

Avg Volume

151,987

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.8

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

693.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$2.60

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.32

Conservative use of debt — low financial risk

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$250,625

Positive — the business generates more cash than it spends

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$109M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$6.25

Target Median

$6.25

Target Low

$6.25

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go